Nuvalent, Inc.
Nuvalent, Inc. (NUVL): 6 pipeline candidates · 2 upcoming catalysts · ~40 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
40.2 months
D/E 0.13
Lead: Phase 3
6 candidates
2 upcoming, next in ~1262d
0 buys · 116 sells (180d)
A transparent, data-derived signal for Nuvalent, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$9.7B
Cash
$159.7M
Quarterly Burn
$92.4M
Runway
40.2 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| Alectinib | Phase 3 |
| Neladalkib | Phase 1/Phase 2 |
| NVL-330 | Phase 1 |
| NVL-520 | Phase 1 |
| nvl-655 | Phase 3 |
| Zidesamtinib | Phase 1 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
261
Total value held
$7.68B
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 17,248,450 | $1.77B |
| fmr llc | 9,274,959 | $950.2M |
| vanguard capital management llc | 4,856,976 | $497.6M |
| blackrock, inc. | 4,824,785 | $494.3M |
| perceptive advisors llc | 3,161,010 | $323.8M |
| ra capital management, l.p. | 2,534,145 | $259.6M |
| vanguard portfolio management llc | 2,500,907 | $256.2M |
| janus henderson group plc | 2,475,558 | $253.7M |
| wellington management group llp | 2,470,491 | $253.1M |
| state street corp | 2,035,831 | $208.6M |
Showing top 10 of 261 institutional holders of Nuvalent, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Nuvalent, Inc.'s pipeline?
Nuvalent, Inc. (NUVL) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nuvalent, Inc.'s lead drug candidate?
Nuvalent, Inc.'s most advanced tracked candidate is Alectinib (Phase 3) for Non-small Cell Lung Cancer.
What is Nuvalent, Inc.'s next catalyst?
Nuvalent, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alec" — expected December 1, 2029.
What is Nuvalent, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nuvalent, Inc. has approximately 40.2 months of cash runway.
What is Nuvalent, Inc.'s market capitalization?
Nuvalent, Inc.'s market capitalization is approximately $9.7B.
Get the full picture on Nuvalent, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.